The Predictive Role of Peripheral Blood Inflammatory Indicators in the Prognosis of Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP
To investigate the predictive role of peripheral inflammatory markers in the prognosis of patients with diffuse large B-cell lymphoma(DLBCL)undergoing R-CHOP therapy,a retrospective analysis was conducted on 96 patients with DLBCL treated with the R-CHOP protocol between January 2019 and January 2023.Baseline characteristics,clinical data,and laboratory tests were collected from the patients,and follow-up observations were conducted.The t-test was used to compare continuous variables between groups,while the x2 test was employed for categorical variables.Kaplan-Meier survival curves were utilized to assess the impact of various markers on the prognostic survival time of DLBCL patients.Both univariate and multivariate Cox regression analyses were per-formed to evaluate the predictive value of NLR,PLR,and LMR in predicting the prognosis of DLBCL patients receiving R-CHOP therapy.Additionally,ROC curves were employed to assess the predictive value of NLR,PLR,and LMR.During the follow-up period ranging from 5 to 43 months,with a median follow-up time of 23.5 months,29 patients succumbed to the disease.Univariate Cox regression analysis revealed significant associations between age,Ann Arbor staging,IPI score,NLR,PLR,LMR,and PS score with overall survival(OS)(all P＜0.05).Variables with statistical significance in the univariate analysis were then included in the multivariate Cox regression analysis,which demonstrated that Ann Arbor staging,IPI score,NLR,PLR,and LMR were independent predictors of OS(P＜0.05).Furthermore,ROC curve analysis demonstrated the predictive value of NLR,PLR,and LMR in the prognosis of DLBCL patients.In conclusion,peripheral inflammatory markers such as NLR,PLR,and LMR exhibit promising predic-tive value in the prognosis of DLBCL patients undergoing R-CHOP therapy.These biomarkers provide valuable information to clini-cians in making treatment decisions and monitoring patient outcomes.
Diffuse large B-cell lymphomaPeripheral inflammatory markersNLRPLRLMRR-CHOPPrognosis
NETL
NSTL
万方数据
